*Pam Koenig is not licensed to practice law. Her activities are directly supervised by members of the firm licensed to practice law in the firm’s Winston-Salem office.

As a Research Consultant for the Medical and Scientific Solutions group with 17 years of experience and an extensive knowledge base of medical issues, Pam is a key contributor to the product liability litigation defense teams.  She consults with defense attorneys and nurses to identify and understand relevant medical and scientific issues in litigation cases. She performs in-depth research into medical issues involved in litigation, including counseling defense teams on occupational exposures and alternate causations.  Her client research has covered a wide range of topics, including the association between asbestos exposure and lung cancer, pulmonary function dynamics in chronic obstructive pulmonary disease, genetic causes of chronic obstructive pulmonary disease, atherosclerosis, and other diseases, oncogenic mutations and tumor markers related to lung cancer, immunohistochemistry and cancer, bacteria exposure in food poisoning and relation to neurological syndromes, and various toxic chemical and drug exposures linked to disease.  Pam has recently investigated possible litigation issues involving COVID-19 as a cause of disease.  A former high school science and math teacher, Pam also spent 20 years as a Respiratory Therapist for Novant Health in Winston-Salem, giving her a strong background in pulmonary disease issues.


Any result the lawyer or law firm may have achieved on behalf of clients in other matters does not necessarily indicate similar results can be obtained for other clients.

  • Worked with Firm attorneys to develop a prediction model of pulmonary function decline in chronic obstructive pulmonary disease to be potentially used to estimate prior values of pulmonary function over time in individual cases.
  • Collaborated with counsel and other team researchers by collecting data to formulate a defense on several possible toxic tort litigation matters, including artificial turf, glyphosate-based herbicide, and the drug, Zantac.
  • Assisted with development of a series of comprehensive defensive strategy documents regarding disease causality and other criteria, including diagnostic, epidemiological, and clinical data, to be used to challenge causal associations and disease outcomes in litigation matters.
  • Has prepared and will continue to prepare analyses of cancer pathology reports, as well as immunohistochemical data, to assist in the development of alternative diagnoses for case litigation.